Skip to content
2000
Volume 21, Issue 4
  • ISSN: 2666-0822
  • E-ISSN: 2666-0830

Abstract

Background

Migraine is a debilitating neuroinflammatory disorder. Patients with migraine often experience elevated levels of depression, anxiety, and stress, which are associated with the frequency and severity of migraine attacks. Curcumin has been shown to have regulatory effects on depression, anxiety, and stress, as well as analgesic properties through various mechanisms. The objective of this study was to assess the impact of nano-curcumin supplementation on depression, anxiety, stress, and clinical manifestations in patients with migraine.

Methodology

This study was conducted as a randomized, double-blind clinical trial. A total of forty-four patients with episodic migraines were recruited for the trial. Stratified randomization was employed to ensure a balanced distribution of participants based on BMI and sex. The patients were equally assigned to two groups using permuted block randomization: 1) the intervention group, which received 80 mg of nano-curcumin, and 2) the placebo (control) group, which received a paraffin-based placebo. The intervention and control periods lasted for 2 months. Anthropometric and demographic data, clinical signs and symptoms (including headache frequency, duration, and severity as reported by the patients), as well as stress, anxiety, and depression scores (using the Dass-21 questionnaire), were recorded before and after the study. The collected data were analyzed using SPSS 22. For normally distributed data, paired t-tests and independent t-tests were utilized. Non-normal data were analyzed using the Wilcoxon test and Mann-Whitney U test. The chi-squared test was employed for categorical variables. To account for confounding factors, the ANCOVA test was conducted. A p-value of ≤ 0.05 was considered statistically significant. The intention-to-treat method was applied to address outliers and missing data.

Results

Based on the findings, the current study demonstrates that supplementation with nano-curcumin can effectively mitigate symptoms of depression and anxiety ( < 0.05). Regarding stress, a noticeable reduction within the nano-curcumin group was observed, although it did not reach statistical significance when compared between groups ( > 0.05). Moreover, nano-curcumin exhibited a significant decrease in the frequency, duration, and severity of headaches ( < 0.05).

Conclusion

Our research findings have shown that supplementation with nano-curcumin can effectively decrease the frequency, severity, and duration of headaches while also alleviating symptoms of depression and anxiety in comparison to the placebo group. Hence, curcumin exhibits significant potential as an adjuvant therapy to enhance the treatment of migraines.

Clinical Trial Registration Number

IRCT20160626028637N2.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822285958240301034959
2024-03-11
2025-11-14

  • From This Site

    /content/journals/cprr/10.2174/0126660822285958240301034959
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BurchR.C. BuseD.C. LiptonR.B. Migraine.Neurol. Clin.201937463164910.1016/j.ncl.2019.06.00131563224
     [Google Scholar]
  2. SteinerT.J. StovnerL.J. BirbeckG.L. Migraine: The seventh disabler.J. Headache Pain2013141110.1186/1129‑2377‑14‑123566305
     [Google Scholar]
  3. OlesenJ. International classification of headache disorders.Lancet Neurol.201817539639710.1016/S1474‑4422(18)30085‑129550365
     [Google Scholar]
  4. YavuzB.G. AydinlarE.I. DikmenP.P. IncesuC. Association between somatic amplification, anxiety, depression, stress and migraine.J. Headache Pain20131415310.1186/1129‑2377‑14‑5323799958
     [Google Scholar]
  5. Yalinay DikmenP. YavuzB.G. AydinlarE.I. The relationships between migraine, depression, anxiety, stress, and sleep disturbances.Acta Neurol. Belg.2015115211712210.1007/s13760‑014‑0312‑024889393
     [Google Scholar]
  6. KarimiL. WijeratneT. CrewtherS.G. EvansA.E. EbaidD. KhalilH. The migraine-anxiety comorbidity among migraineurs: A systematic review.Front. Neurol.20211161337210.3389/fneur.2020.61337233536997
     [Google Scholar]
  7. StubberudA. BuseD.C. KristoffersenE.S. LindeM. TronvikE. Is there a causal relationship between stress and migraine? Current evidence and implications for management.J. Headache Pain202122115510.1186/s10194‑021‑01369‑634930118
     [Google Scholar]
  8. JahangirS. AdjepongD. Al-ShamiH.A. MalikB.H. Dennis AdjepongM. Is there an association between migraine and major depressive disorder? a narrative review.Cureus2020126e855110.7759/cureus.855132670688
     [Google Scholar]
  9. XuX.Y. MengX. LiS. GanR.Y. LiY. LiH.B. Bioactivity, health benefits, and related molecular mechanisms of curcumin: Current progress, challenges, and perspectives.Nutrients20181010155310.3390/nu1010155330347782
     [Google Scholar]
  10. SasakiH. SunagawaY. TakahashiK. Innovative preparation of curcumin for improved oral bioavailability.Biol. Pharm. Bull.201134566066510.1248/bpb.34.66021532153
     [Google Scholar]
  11. KanaiM. ImaizumiA. OtsukaY. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.Cancer Chemother. Pharmacol.2012691657010.1007/s00280‑011‑1673‑121603867
     [Google Scholar]
  12. DeogadeS.C. GhateS. Curcumin: Therapeutic applications in systemic and oral health.Int J Biol Pharm Res201564281290
     [Google Scholar]
  13. AbdolahiM. JafariehA. SarrafP. The neuromodulatory effects of ω-3 fatty acids and nano-curcumin on the COX-2/iNOS network in migraines: A clinical trial study from gene expression to clinical symptoms.Endocr. Metab. Immune Disord. Drug Targets201919687488410.2174/187153031966619021217014030760195
     [Google Scholar]
  14. AsadiS. GholamiM.S. SiassiF. QorbaniM. SotoudehG. Beneficial effects of nano‐curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double‐blind, placebo‐controlled clinical trial.Phytother. Res.202034489690310.1002/ptr.657131788880
     [Google Scholar]
  15. LinT.Y. LuC.W. WangC.C. WangY.C. WangS.J. Curcumin inhibits glutamate release in nerve terminals from rat prefrontal cortex: Possible relevance to its antidepressant mechanism.Prog. Neuropsychopharmacol. Biol. Psychiatry20113571785179310.1016/j.pnpbp.2011.06.01221741425
     [Google Scholar]
  16. KulkarniS.K. BhutaniM.K. BishnoiM. Antidepressant activity of curcumin: Involvement of serotonin and dopamine system.Psychopharmacology2008201343544210.1007/s00213‑008‑1300‑y18766332
     [Google Scholar]
  17. LimJ.H. KwonT.K. Curcumin inhibits phorbol myristate acetate (PMA)-induced MCP-1 expression by inhibiting ERK and NF-κB transcriptional activity.Food Chem. Toxicol.2010481475210.1016/j.fct.2009.09.01319766691
     [Google Scholar]
  18. RamaholimihasoT. BouazzaouiF. KaladjianA. Curcumin in depression: Potential mechanisms of action and current evidence—a narrative review.Front. Psychiatry20201157253310.3389/fpsyt.2020.57253333329109
     [Google Scholar]
  19. LeeJ.Y. ShinT.J. ChoiJ.M. Antinociceptive curcuminoid, KMS4034, effects on inflammatory and neuropathic pain likely via modulating TRPV1 in mice.Br. J. Anaesth.2013111466767210.1093/bja/aet17623719767
     [Google Scholar]
  20. LimcharoenT. MuangnoiC. Dasuni WasanaP.W. Improved antiallodynic, antihyperalgesic and anti-inflammatory response achieved through potential prodrug of curcumin, curcumin diethyl diglutarate in a mouse model of neuropathic pain.Eur. J. Pharmacol.202189917400810.1016/j.ejphar.2021.17400833705800
     [Google Scholar]
  21. XiaoL. DingM. FernandezA. ZhaoP. JinL. LiX. Curcumin alleviates lumbar radiculopathy by reducing neuroinflammation, oxidative stress and nociceptive factors.Eur. Cell. Mater.20173327929310.22203/eCM.v033a2128485773
     [Google Scholar]
  22. SedighiyanM. JafariE. AtharS.S. The effects of nano-curcumin supplementation on leptin and adiponectin in migraine patients: A double-blind clinical trial study from gene expression to clinical symptoms.Endocr. Metab. Immune Disord. Drug Targets202323571172010.2174/187153032266622070110081735786344
     [Google Scholar]
  23. SedighiyanM. AbdolahiM. JafariE. The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: A double blind clinical trial study.BMC Res. Notes202215118910.1186/s13104‑022‑06074‑435606882
     [Google Scholar]
  24. HonarvarN.M. SoveidN. AbdolahiM. DjalaliM. HatamiM. KarzarN.H. Anti-neuroinflammatory properties of n-3 fatty acids and nano-curcumin on migraine patients from cellular to clinical insight: A randomized, double-blind and placebo-controlled trial.Endocr. Metab. Immune Disord. Drug Targets202121236537310.2174/22123873MTA45NjQk432727335
     [Google Scholar]
  25. AntonyM.M. BielingP.J. CoxB.J. EnnsM.W. SwinsonR.P. Psychometric properties of the 42-item and 21-item versions of the depression anxiety stress scales in clinical groups and a community sample.Psychol. Assess.199810217618110.1037/1040‑3590.10.2.176
     [Google Scholar]
  26. StovnerL.J. NicholsE. SteinerT.J. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the global burden of disease study 2016.Lancet Neurol.2018171195497610.1016/S1474‑4422(18)30322‑330353868
     [Google Scholar]
  27. SchroederR.A. BrandesJ. BuseD.C. Sex and gender differences in migraine—evaluating knowledge gaps.J. Womens Health201827896597310.1089/jwh.2018.727430129895
     [Google Scholar]
  28. ParohanM. SarrafP. JavanbakhtM.H. ForoushaniA.R. Ranji-BurachalooS. DjalaliM. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial.Nutr. Neurosci.202124431732610.1080/1028415X.2019.162777031241007
     [Google Scholar]
  29. RezaieS. AskariG. KhorvashF. TarrahiM.J. AmaniR. Effects of curcumin supplementation on clinical features and inflammation, in migraine patients: A double-blind controlled, placebo randomized clinical trial.Int. J. Prev. Med.20211216135070194
     [Google Scholar]
  30. SahebkarA. HenrotinY. Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and meta-analysis of randomized controlled trials.Pain Med.20161761192120210.4103/ijpvm.IJPVM‑405‑2026814259
     [Google Scholar]
  31. ZhaoG. ShiY. GongC. Curcumin exerts antinociceptive effects in cancer-induced bone pain via an endogenous opioid mechanism.Front. Neurosci.20211569686110.3389/fnins.2021.69686134539332
     [Google Scholar]
  32. KunnumakkaraA.B. HegdeM. ParamaD. Role of turmeric and curcumin in prevention and treatment of chronic diseases: Lessons learned from clinical trials.ACS Pharmacol. Transl. Sci.20236444751810.1021/acsptsci.2c0001237082752
     [Google Scholar]
  33. AbdolahiM. SarrafP. JavanbakhtM.H. A novel combination of ω-3 fatty acids and nano-curcumin modulates interleukin-6 gene expression and high sensitivity C-reactive protein serum levels in patients with migraine: A randomized clinical trial study.CNS Neurol. Disord. Drug Targets201817643043810.2174/187152731766618062510164329938621
     [Google Scholar]
  34. KamarudinN. HisamuddinN. OngH. Analgesic effect of 5-(3,4-Dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one in experimental animal models of nociception.Molecules2018239209910.3390/molecules2309209930134576
     [Google Scholar]
  35. Zare BidakiF. ChaichianS. Arbabi BidgoliS. The role of oral Curcumin Nanomicell on improvement of menstrual disorders, depression and anxiety in women with Polycystic Ovarian Syndrome.Majallah-i Zanan, Mamai va Nazai-i Iran20212415566
     [Google Scholar]
  36. LoprestiA.L. SmithS.J. ReaA. MichelS. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: A randomised, double-blind, placebo-controlled study.BMC Complement. Med. Ther.2021211117
     [Google Scholar]
  37. Fusar-PoliL. VozzaL. GabbiadiniA. Curcumin for depression: A meta-analysis.Crit. Rev. Food Sci. Nutr.202060152643265310.1080/10408398.2019.165326031423805
     [Google Scholar]
  38. NgQ.X. KohS.S.H. ChanH.W. HoC.Y.X. Clinical use of curcumin in depression: A meta-analysis.J. Am. Med. Dir. Assoc.201718650350810.1016/j.jamda.2016.12.07128236605
     [Google Scholar]
  39. RubabS. NaeemK. RanaI. Enhanced neuroprotective and antidepressant activity of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced depression and anxiety rat model.Int. J. Pharm.202160312067010.1016/j.ijpharm.2021.12067033964337
     [Google Scholar]
  40. YuJ.J. PeiL.B. ZhangY. WenZ.Y. YangJ.L. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study.J. Clin. Psychopharmacol.201535440641010.1097/JCP.000000000000035226066335
     [Google Scholar]
  41. WuA. NobleE.E. TyagiE. YingZ. ZhuangY. Gomez-PinillaF. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders.Biochim. Biophys. Acta Mol. Basis Dis.20151852595196110.1016/j.bbadis.2014.12.00525550171
     [Google Scholar]
/content/journals/cprr/10.2174/0126660822285958240301034959
Loading
Efficacy of Nano-curcumin Supplementation on Depression, Anxiety, Stress and Clinical Symptoms in Migraine Patients: A Randomized Double-blind Clinical Trial
Curr Psyc Res Rev 21, 577 (2025); https://doi.org/10.2174/0126660822285958240301034959
/content/journals/cprr/10.2174/0126660822285958240301034959
/content/journals/cprr/10.2174/0126660822285958240301034959
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anxiety; curcumin; DASS-21; depression; headache; migraine; stress

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test